You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 261 No. 17, May 5, 1989 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (71)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Testosterone Replacement With Transdermal Therapeutic Systems

Physiological Serum Testosterone and Elevated Dihydrotestosterone Levels

Glenn R. Cunningham, MD; Emilia Cordero, RN; Jack I. Thornby, PhD

JAMA. 1989;261(17):2525-2530.


Abstract

Testosterone was administered transdermally to hypogonadal men under three protocols. In the first protocol, it was shown that peak levels of testosterone were achieved three to eight hours after scrotal application of a transdermal therapeutic system containing 5, 10, or 15 mg of testosterone, and values at 22 hours were greater than 60% of peak values. In the second protocol, patients were treated with 10-mg systems for four weeks followed by 15-mg systems for eight weeks. Serum samples were obtained three to five hours after application of the transdermal therapeutic system. Testosterone increased from a pretreatment level (mean ± SE) of 1.5 ± 0.4 nmol/L to 15.2 ±3.4 nmol/L at four weeks, 18.6 ± 3.3 nmol/L at eight weeks, and 17.3 ± 2.8 nmol/L at 12 weeks. The serum testosterone/dihydrotestosterone (DHT) ratio fell from 4.53 to 2.47 at four weeks and was similar at eight and 12 weeks, reflecting a greater rise in DHT with this route of treatment (normal testosterone/DHT ratio, 9/1 to 12/1). Eight patients were treated with the 15-mg systems for an additional year. Seven of the eight were compliant and maintained serum testosterone levels (at six time points from two to 12 months [mean ± SE]) ranging from 11.5 ±1.2 to 44.9 ±2.4 nmol/L. It was possible to achieve physiological serum levels of testosterone by transdermal administration of testosterone in two thirds of our hypogonadal men.

(JAMA. 1989;261:2525-2530)



Author Affiliations

From the Medicine (Dr Cunningham and Ms Cordero) and Psychiatry (Dr Thornby) Services, Veterans Administration Medical Center and Baylor College of Medicine, Houston.


Footnotes

Reprint requests to Endocrinology Section (111E), Veterans Administration Medical Center, 2002 Holcombe Blvd, Houston, TX 77030 (Dr Cunningham).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Testosterone Replacement Therapy for Older Men
Wald et al.
J Androl 2006;27:126-132.
FULL TEXT  

New Testosterone Buccal System (Striant) Delivers Physiological Testosterone Levels: Pharmacokinetics Study in Hypogonadal Men
Wang et al.
J. Clin. Endocrinol. Metab. 2004;89:3821-3829.
ABSTRACT | FULL TEXT  

Testosterone Gel Supplementation for Men With Refractory Depression: A Randomized, Placebo-Controlled Trial
Pope et al.
Am. J. Psychiatry 2003;160:105-111.
ABSTRACT | FULL TEXT  

Long-Term Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men
Swerdloff et al.
J. Clin. Endocrinol. Metab. 2000;85:4500-4510.
ABSTRACT | FULL TEXT  

Testosterone--Fountain of Youth or Drug of Abuse?
Hayes
J. Clin. Endocrinol. Metab. 2000;85:3020-3023.
FULL TEXT  

Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men
Wang et al.
J. Clin. Endocrinol. Metab. 2000;85:2839-2853.
ABSTRACT | FULL TEXT  

Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study
Wang et al.
J. Clin. Endocrinol. Metab. 2000;85:964-969.
ABSTRACT | FULL TEXT  

Pharmacokinetic Characteristics, Efficacy, and Safety of Buccal Testosterone in Hypogonadal Males: A Pilot Study
Dobs et al.
J. Clin. Endocrinol. Metab. 1998;83:33-39.
ABSTRACT | FULL TEXT  

Issues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes' urine
Catlin et al.
Clin. Chem. 1997;43:1280-1288.
ABSTRACT | FULL TEXT  

Emerging Issues in Androgen Replacement Therapy
Bhasin and Bremner
J. Clin. Endocrinol. Metab. 1997;82:3-8.
FULL TEXT  

Review: Medication Delivery in the Short-Bowel Syndrome
McFadden et al.
JPEN J Parenter Enteral Nutr 1993;17:180-186.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.